• Protecting Lysosomal Repair Signals in Translation

  2026-09-18

  Lysosomal repair is a dynamic, protease-sensitive process that can be distorted during sample preparation. This thought-leadership article connects TECPR1-mediated membrane tubulation under energy stress with practical strategies for preserving protein complexes, phosphorylation-sensitive signals, and native structure. It explains how an EDTA-free formulation supports mechanistic studies without introducing unnecessary metal chelation, while offering protocol guidance, competitive positioning, translational cautions, and a forward-looking framework for connecting organelle biology with reproducible assay design.

• Cytochalasin D in Ocular Uptake Assays

  2026-09-17

  Cytochalasin D provides a mechanistic way to test whether actin-dependent processes contribute to nanoparticle uptake in corneal epithelial models. This article translates recent ocular delivery findings into practical assay controls while separating cytoskeletal effects from toxicity, cell-cycle changes, and nonspecific loss of cell function.

• miR-18a, ALOXE3, and Glioblastoma Progression

  2026-09-17

  The reference study identifies a miR-18a/ALOXE3 axis that links ferroptosis resistance, 12-HETE secretion, and glioblastoma cell migration. Its integrated genetic, biochemical, and orthotopic mouse experiments provide a framework for studying how lipid metabolism and GPCR-associated signaling jointly drive GBM progression.

• Pexidartinib: A Causal Tool for TAM Assays

  2026-09-16

  Pexidartinib (PLX3397) can serve as a mechanistic perturbation tool for dissecting CSF1R-dependent tumor-associated macrophage biology. This guide explains how to pair CSF1R inhibition with SPP1-focused assays to distinguish macrophage depletion, phenotypic remodeling, and direct anti-tumor effects.

• AST 487 in a KDM4A-Led Translational Strategy

  2026-09-16

  KDM4A is a compelling dependency in malignant pleural mesothelioma, but translating that biology requires more than a single inhibitor experiment. This article examines the evidence, proposes a decision-grade validation workflow, and positions AST 487 as a carefully bounded research reagent rather than an unproven substitute for direct KDM4A inhibition.

• RBMS1 Loss Enables PD-L1 Blockade in TNBC

  2026-09-15

  The reference study identifies the RNA-binding protein RBMS1 as a regulator of immune-cold triple-negative breast cancer through control of PD-L1 stability. Its mechanistic link to B4GALT1 mRNA stability, PD-L1 glycosylation, and tumor-cell immune evasion provides a rationale for combining RBMS1 depletion with T-cell-based or checkpoint-directed therapies.

• Taltirelin Acetate: Research Workflows

  2026-09-15

  Taltirelin acetate connects TRHR1-centered neurobiology with practical Parkinson’s disease, itch, sleep, and formulation workflows. This guide translates published dissolution findings into assay design, dosing, controls, and troubleshooting decisions.

• HyperScribe T7 High Yield Cy3 RNA Labeling Kit Guide

  2026-09-14

  Build bright, reproducible RNA probes for in situ hybridization and Northern blot workflows while tuning Cy3-UTP incorporation to preserve transcription performance. This practical guide connects fluorescent probe design with mRNA-delivery research and provides executable setup, optimization, and troubleshooting strategies.

• Escitalopram Beyond the Product Page

  2026-09-14

  Escitalopram offers translational researchers a defined serotonergic reference point for connecting transporter pharmacology with antidepressant and anxiety-related outcomes. This article examines assay strategy, clinical interpretation, and the limits of extrapolating 5-HT reuptake inhibition into regimen-level efficacy.

• NAD+ Workflows for Stress-Response Assays

  2026-09-13

  Build more informative stress-adaptation experiments by pairing NAD+ redox measurements with caspase, PARP1, autophagy, and DNA-damage endpoints. This practical workflow distinguishes metabolic change from mechanistic evidence and provides starting conditions for cell-free, lysate-based, and breast cancer cell assays.

• Super-Enhancer–FOXA1–SLC7A11 Axis in Prostate Cancer

  2026-09-12

  The reference study defines a super-enhancer–FOXA1–SLC7A11 regulatory axis that links transcriptional control to disulfidptosis and prostate cancer progression. Its integrated genomic, epigenetic, pharmacological, and CRISPR-based design provides a framework for testing how nutrient stress reshapes cancer-cell vulnerability.

• TG003 Cdc2-like Kinase Inhibitor Workflows

  2026-09-11

  TG003 enables reversible control of Clk-dependent splicing, from splice site selection research to exon-skipping studies. Its broader Clk and CK1 activity also makes it a useful mechanistic probe for testing how CLK2-linked DNA repair may influence platinum response, provided target engagement and selectivity are carefully validated.

• VERTIS CV: Ertugliflozin and Cardiovascular Outcomes

  2026-09-11

  The VERTIS CV trial established that ertugliflozin was noninferior to placebo for major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Its rigorous event-driven design also showed numerically favorable, but not statistically superior, trends for heart-failure and renal outcomes, clarifying both the evidence and limits of SGLT2 inhibitor benefit in this population.

• PKH26 Red Fluorescent Cell Linker Kit Guide

  2026-09-10

  The PKH26 Red Fluorescent Cell Linker Kit supplies a membrane-associated red label for cell tracing in vitro and in vivo and proliferation-oriented tracking when fluorescence is measured over time. It is intended for cell membrane lipid region fluorescent labeling, not intracellular labeling, non-membrane targets, or using fluorescence alone as a viability or cell-identity marker.

• Telmisartan in Cardiac Hypertrophy Workflows

  2026-09-10

  Use Telmisartan as a receptor-proximal control to test whether angiotensin II-driven remodeling depends on AT1R signaling. This workflow pairs hypertrophy phenotyping with RIP3/CaMKII, JAK2/STAT3, and NF-κB readouts to distinguish upstream blockade from downstream pathway modulation.

7900 records 4/527 page Previous Next 12345 下5页 Last page